Answers are grounded in this paper and cite their sources.
Aim: To identify serum biomarkers for non-small cell lung cancer (NSCLC) and assess their potential for early diagnosis. Experimental: MB-WCX coupled with MALDI-TOF MS was utilized to profile serum samples from 64 NSCLC patients and 64 healthy subjects, followed by ClinProTools software and Liquid chromatography-electrospray ionization-tandem mass spectrometry(LC-ESI-MS/MS) for recognition and characterization of differentially expressed peaks. Enzyme-linked immunosorbent assay (ELISA) confirmed protein concentrations, while The Cancer Genome Atlas (TCGA) database was leveraged for validation of candidate biomarkers in a larger cohort. Results: 39 distinct proteomic m/z peaks were identified for NSCLC subjects, with five of these peaks significantly distinguishing NSCLC from healthy controls (HC). A model developed using the GA (Genetic Algorithm) with ClinProt data demonstrated a sensitivity of 84.72% and a specificity of 88.68% in identifying NSCLC patients. Peaks 2 through 5 were observed to be downregulated in the NSCLC group. Notably, a peptide peak, Peak 1, with an m/z value of 1,866, identified as a fragment of TUBB, was upregulated in NSCLC. ELISA validated the increased serum TUBB levels in NSCLC patients (P < 0.001). Furthermore, analysis of TUBB expression in lung cancer tissues through TCGA data revealed elevated TUBB expression in lung cancer tissues. Conclusions: Serum TUBB is identified as a potential diagnostic biomarker for NSCLC, which may benefit early diagnosis and enhance the survival rate of NSCLC patients.
No takes yet. Share an insight, caveat, or question.
Song et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: